PEDMARQSI Approved in Australia for Cisplatin Hearing Loss

Norgine Secures Australian Regulatory Approval for PEDMARQSI® Pediatric Hearing Protection

In a meaningful advancement for pediatric oncology, pharmaceutical company Norgine has successfully obtained regulatory approval from Australia’s Therapeutic Goods Administration (TGA) for PEDMARQSI® (anhydrous sodium thiosulfate). The approval authorizes the medication for prevention of cisplatin-induced ototoxicity—chemotherapy-related hearing loss—in pediatric patients ranging from one month to under 18 years of age who are being treated for localized, non-metastatic solid tumors.

This regulatory milestone represents a critical development in supportive cancer care, addressing a significant and often overlooked side effect of one of oncology’s most potent chemotherapeutic agents. Cisplatin remains a cornerstone of pediatric cancer treatment protocols, yet its use carries substantial risks of permanent hearing damage that can profoundly impact a child’s development, education, and quality of life.

Understanding Cisplatin-Induced Hearing Loss in Children

Cisplatin-induced ototoxicity represents one of the most challenging long-term complications facing pediatric cancer survivors. The chemotherapy agent damages the delicate hair cells within the inner ear, potentially causing irreversible hearing loss that may range from mild high-frequency impairment to profound deafness. Unlike many chemotherapy side effects that may resolve after treatment concludes, cisplatin-related hearing damage is typically permanent and cumulative, worsening with increasing drug exposure.

For children undergoing cancer treatment, this complication carries particularly severe implications. Hearing loss during critical developmental years can impair speech acquisition, language development, educational attainment, and social integration. The psychological and developmental consequences often extend far beyond the immediate medical impact, affecting a child’s ability to learn, communicate, and participate fully in family and community life.

Despite these serious consequences, treatment options to prevent this toxicity have remained limited, leaving oncologists and families with an untenable choice: forgo beneficial chemotherapy or accept the risk of permanent hearing damage. PEDMARQSI® changes this calculus by providing a validated protective mechanism.

How PEDMARQSI® Works to Protect Hearing

PEDMARQSI® operates through a well-established pharmacological mechanism: anhydrous sodium thiosulfate functions as a cytoprotective agent that binds to cisplatin, reducing the chemotherapy agent’s ability to damage healthy cells while maintaining its anti-cancer efficacy. By neutralizing cisplatin’s toxic effects on inner ear tissue, the medication preserves hearing function without compromising cancer treatment effectiveness—a critical distinction that allows clinicians to prescribe optimal chemotherapy regimens without the guilt of knowingly causing permanent collateral damage.

The approval in Australia follows rigorous evaluation of clinical evidence demonstrating the medication’s safety and efficacy in the pediatric population. Regulatory agencies worldwide have increasingly recognized the importance of otoprotective strategies, reflecting growing acknowledgment that long-term quality of life matters as much as initial cancer cure rates.

Implications for Pediatric Cancer Care

This Australian approval expands the arsenal of supportive care options available to pediatric oncology teams across the region. Clinicians treating children with solid tumors requiring cisplatin chemotherapy can now implement evidence-based strategies to mitigate one of the most debilitating long-term treatment consequences. The availability of an approved otoprotective agent fundamentally changes the risk-benefit conversation with families facing pediatric cancer diagnosis.

Beyond the immediate clinical applications, this approval signals market recognition and regulatory confidence in protective strategies that optimize treatment outcomes by addressing toxicity rather than merely tolerating it. As healthcare systems worldwide increasingly focus on survivorship quality and long-term functional outcomes, medications that preserve children’s developmental trajectories command growing importance in cancer care protocols.

Norgine’s Contribution to Pediatric Oncology

Norgine’s development and regulatory pursuit of PEDMARQSI® reflects a commitment to addressing unmet needs in pediatric medicine—a therapeutic area where commercial incentives often lag behind medical necessity. The company’s investment in bringing this protective therapy to Australian patients demonstrates recognition that reducing treatment-related toxicity represents genuine progress in oncology, not merely pharmaceutical market expansion.

The Australian approval joins approvals in other global markets, creating an expanding geography where pediatric cancer patients can access this protective therapy. As regulatory approvals accumulate across different regions, the medication becomes increasingly integrated into standard supportive care protocols, ultimately benefiting children worldwide who face cisplatin-based chemotherapy.

Looking Forward

The TGA approval of PEDMARQSI® in Australia establishes an important precedent and practical option for pediatric oncologists treating children with solid tumors. By providing regulatory-approved protection against one of chemotherapy’s most serious long-term complications, the approval reflects evolving standards in cancer care that prioritize both cure and quality of life. For children undergoing cancer treatment and their families, this represents meaningful progress in preserving the developmental and functional futures of young cancer survivors.